GlassScriptPhysician profile
Nolan Weinberg
NPI 1720013303
$697.84
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $668 · 2020: $11.44 · 2021: $18.61.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $142.04 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $87.17 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $72.88 | 2019 | |
| Novartis Pharmaceuticals Corporation | $55.95 | 2019 | |
| Abbvie INC. | $39.35 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $36.61 | 2019 | |
| Astellas Pharma US INC | $30.70 | 2019 | |
| Allergan, INC. | $27.06 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.04 | 2019 | |
| Janssen Pharmaceuticals, INC | $25.12 | 2019 | |
| Lilly USA, LLC | $24.47 | 2019 | |
| Pfizer INC. | $24.25 | 2019 | |
| Amarin Pharma, INC. | $22.64 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.71 | 2019 | |
| Novo Nordisk INC | $15.00 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $14.13 | 2019 | |
| Genentech USA, INC. | $13.13 | 2019 | |
| Aytu Biopharma, INC. | $13.00 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.59 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nolan Weinberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.